Newron Pharmaceuticals Shares Promising Data at 2024 SIRS Congress

Newron Pharmaceuticals S.p.A., a leading biopharmaceutical company, recently presented significant data and future clinical development plans for evenamide at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) in Florence, Italy. This event highlighted the potential of evenamide as an add-on therapy for treatment-resistant schizophrenia (TRS) through studies 014/015 and also provided an outlook on its development.

The data from study 014/015, a phase II trial, demonstrated that evenamide, when added to antipsychotics, was well tolerated by patients with TRS. This trial showed that evenamide could provide a sustained, clinically significant benefit over a one-year treatment period, with more than 70% of patients experiencing a notable reduction in disease severity. Remarkably, a quarter of the patients achieved remission, with no patients relapsing during the study.

Newron is set to initiate a pivotal phase III trial for TRS, following the encouraging outcomes of study 014/015, hoping to confirm evenamide's benefits further. In addition, Newron explored evenamide's application in a separate pivotal study (study 008A) involving non-TRS patients showing inadequate response to second-generation antipsychotics, with results anticipated in late April 2024.

The presentations and posters shared at the SIRS congress offered a detailed view of evenamide's potential as a transformative treatment for schizophrenia, particularly for those unresponsive to current therapies. This ongoing research and development underscore Newron's commitment to advancing care for CNS diseases.